INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 45h ago
HOUSE PTR5h ago
SEC 13F5h ago
ROBINHOOD CHAIN5h ago
SEC FORM 4/Open-market saleVerified dataRule 10b5-1 plan

Friedman Paul A sold MDGL

Director · MADRIGAL PHARMACEUTICALS, INC. · Common Stock

Side
SELL
Value
$79K
Shares
148
Price
$535.29
Executed
Jan 9, 2026
Disclosed
Jan 13, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Jan 9 executedJan 13, 2026 disclosed

MDGL · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
13/ 100 · ROUTINE
Methodology →
  • Transaction type+6 / 20

    Open-market sale

  • Relative size+4 / 25

    $79K reported value · 0.1% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering+5 / 15

    1 other actor traded the same direction within 14 days

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · MDGL

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    4
    SJ
    Sibold William JohnDirector, President and CEO
    MDGLMADRIGAL PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$415K
    761 sh
    		Sep 11, 2026Sep 11, 2026
    traded Sep 11, 2026
    		+0dSEC FORM 4

    Evidence

    4
    SJ
    Sibold William JohnDirector, President and CEO
    MDGLMADRIGAL PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$652K
    1,202 sh
    		Sep 11, 2026Sep 11, 2026
    traded Sep 11, 2026
    		+0dSEC FORM 4

    Evidence

    7
    SJ
    Sibold William JohnDirector, President and CEO
    MDGLMADRIGAL PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$345K
    644 sh
    		Sep 9, 2026Sep 11, 2026
    traded Sep 9, 2026
    		+2dSEC FORM 4

    Evidence

    1
    SJ
    Sibold William JohnDirector, President and CEO
    MDGLMADRIGAL PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$66K
    120 sh
    		Sep 11, 2026Sep 11, 2026
    traded Sep 11, 2026
    		+0dSEC FORM 4

    Evidence

    7
    SJ
    Sibold William JohnDirector, President and CEO
    MDGLMADRIGAL PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$280K
    520 sh
    		Sep 9, 2026Sep 11, 2026
    traded Sep 9, 2026
    		+2dSEC FORM 4

    Evidence

    4
    SJ
    Sibold William JohnDirector, President and CEO
    MDGLMADRIGAL PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$837K
    1,539 sh
    		Sep 11, 2026Sep 11, 2026
    traded Sep 11, 2026
    		+0dSEC FORM 4

    Evidence

    4
    SJ
    Sibold William JohnDirector, President and CEO
    MDGLMADRIGAL PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$87K
    160 sh
    		Sep 9, 2026Sep 11, 2026
    traded Sep 9, 2026
    		+2dSEC FORM 4

    Evidence

    4
    SJ
    Sibold William JohnDirector, President and CEO
    MDGLMADRIGAL PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$116K
    215 sh
    		Sep 9, 2026Sep 11, 2026
    traded Sep 9, 2026
    		+2dSEC FORM 4

    Evidence

    7
    SJ
    Sibold William JohnDirector, President and CEO
    MDGLMADRIGAL PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$344K
    640 sh
    		Sep 9, 2026Sep 11, 2026
    traded Sep 9, 2026
    		+2dSEC FORM 4

    Evidence

    7
    SJ
    Sibold William JohnDirector, President and CEO
    MDGLMADRIGAL PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$277K
    522 sh
    		Sep 9, 2026Sep 11, 2026
    traded Sep 9, 2026
    		+2dSEC FORM 4

    Evidence

    4
    SJ
    Sibold William JohnDirector, President and CEO
    MDGLMADRIGAL PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$196K
    368 sh
    		Sep 9, 2026Sep 11, 2026
    traded Sep 9, 2026
    		+2dSEC FORM 4

    Evidence

    7
    SJ
    Sibold William JohnDirector, President and CEO
    MDGLMADRIGAL PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$273K
    512 sh
    		Sep 9, 2026Sep 11, 2026
    traded Sep 9, 2026
    		+2dSEC FORM 4

    Evidence

    4
    SJ
    Sibold William JohnDirector, President and CEO
    MDGLMADRIGAL PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$212K
    396 sh
    		Sep 9, 2026Sep 11, 2026
    traded Sep 9, 2026
    		+2dSEC FORM 4

    Evidence

    7
    SJ
    Sibold William JohnDirector, President and CEO
    MDGLMADRIGAL PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$558K
    1,040 sh
    		Sep 9, 2026Sep 11, 2026
    traded Sep 9, 2026
    		+2dSEC FORM 4

    Evidence

    4
    SJ
    Sibold William JohnDirector, President and CEO
    MDGLMADRIGAL PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$196K
    362 sh
    		Sep 9, 2026Sep 11, 2026
    traded Sep 9, 2026
    		+2dSEC FORM 4

    Evidence

    0
    SJ
    Sibold William JohnDirector, President and CEO
    MDGLMADRIGAL PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$32K
    60 sh
    		Sep 11, 2026Sep 11, 2026
    traded Sep 11, 2026
    		+0dSEC FORM 4

    Evidence

    7
    SJ
    Sibold William JohnDirector, President and CEO
    MDGLMADRIGAL PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$273K
    505 sh
    		Sep 9, 2026Sep 11, 2026
    traded Sep 9, 2026
    		+2dSEC FORM 4

    Evidence

    4
    SJ
    Sibold William JohnDirector, President and CEO
    MDGLMADRIGAL PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$69K
    131 sh
    		Sep 9, 2026Sep 11, 2026
    traded Sep 9, 2026
    		+2dSEC FORM 4

    Evidence

    4
    SJ
    Sibold William JohnDirector, President and CEO
    MDGLMADRIGAL PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$184K
    347 sh
    		Sep 9, 2026Sep 11, 2026
    traded Sep 9, 2026
    		+2dSEC FORM 4

    Evidence

    1
    SJ
    Sibold William JohnDirector, President and CEO
    MDGLMADRIGAL PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$57K
    106 sh
    		Sep 11, 2026Sep 11, 2026
    traded Sep 11, 2026
    		+0dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001628280-26-001976
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jan 9, 2026
    Published
    Jan 13, 2026
    Ingested by INSIDER
    Nov 5, 04:23 UTC
    Last re-read
    Nov 5, 04:23 UTC

    Extracted facts

    Filer
    Friedman Paul A
    Role
    Director
    Transaction
    Open-market saleAs filed: “S”
    Asset
    MADRIGAL PHARMACEUTICALS, INC.
    Ticker
    MDGL
    Shares
    148
    Price per share
    $535.29
    Value
    $79,223
    Execution date (reported)
    Jan 9, 2026
    Owned after transaction
    189.3K shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    4

    Calculation

    Value = shares × reported price per share

    • Shares: 148
    • Price: $535.2886

    = $79,223

    What this establishes

    Friedman Paul A filed this Form 4 reporting a open-market sale of MDGL on Jan 9, 2026. It became public on Jan 13, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director
    Friedman Paul Acik:0001236927
    Issuer
    MADRIGAL PHARMACEUTICALS, INC.cik:0001157601

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.